Literature DB >> 19807206

De-risking drug discovery with ADDME -- avoiding drug development mistakes early.

Katya Tsaioun1, Mary Jacewicz.   

Abstract

The advent of early Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) screening has increased the elimination rate of weak drug candidates early in the drug-discovery process, and decreased the proportion of compounds failing in clinical trials for ADMET reasons. This paper reviews the history of ADMET screening and why it has become so important in drug discovery and development. Assays that have been developed in response to specific needs, and improvements in technology that result in higher throughput and greater accuracy of prediction of human mechanisms of toxicity, are discussed. The paper concludes with the authors' forecast of new models that will better predict human efficacy and toxicity. 2009 FRAME.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19807206     DOI: 10.1177/026119290903701S10

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN: 0261-1929            Impact factor:   1.303


  3 in total

1.  New surface radiolabeling schemes of super paramagnetic iron oxide nanoparticles (SPIONs) for biodistribution studies.

Authors:  Prakash D Nallathamby; Ninell P Mortensen; Heather A Palko; Mike Malfatti; Catherine Smith; James Sonnett; Mitchel J Doktycz; Baohua Gu; Ryan K Roeder; Wei Wang; Scott T Retterer
Journal:  Nanoscale       Date:  2015-04-21       Impact factor: 7.790

2.  Drug-like property profiling of novel neuroprotective compounds to treat acute ischemic stroke: guidelines to develop pleiotropic molecules.

Authors:  Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2013-06       Impact factor: 6.829

3.  KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Authors:  Wei Wang; Lin Ao; Elizabeth R Rayburn; Hongxia Xu; Xiangrong Zhang; Xu Zhang; Subhasree Ashok Nag; Xuming Wu; Ming-Hai Wang; Hui Wang; Erwin G Van Meir; Ruiwen Zhang
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.